US Patent

US9522188 — Abuse resistant transmucosal drug delivery device

Formulation · Assigned to Biodelivery Sciences International Inc · Expires 2035-04-24 · 9y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a bioerodable transmucosal delivery device for abusable drugs, such as Subutex, with an abuse-resistant matrix.

USPTO Abstract

The present invention relates to a solid pharmaceutical dosage form for abusable drug delivery with reduced illicit abuse potential. The dosage form is presented as a bioerodable transmucosal delivery device that includes an abusable drug and an antagonist to the abusable drug associated with an abuse-resistant matrix. The devices of the invention may be in the form of a layered film or a tablet. Upon application in a non-abusive manner, the device adheres to the mucosal surface, providing transmucosal drug delivery of the drug with minimal absorption of the antagonist into systemic circulation.

Drugs covered by this patent

Patent Metadata

Patent number
US9522188
Jurisdiction
US
Classification
Formulation
Expires
2035-04-24
Drug substance claim
No
Drug product claim
Yes
Assignee
Biodelivery Sciences International Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.